-
Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)
08 Jan 2025 12:25 GMT
… 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the … Company. About Arch Biopartners Arch Biopartners Inc. is a … For more information on Arch Biopartners’ science and drug platform … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners doses first patient in Canada for phase II trial of LSALT peptide to treat cardiac surgery associated acute kidney injury
13 Nov 2024 06:14 GMT
Arch Biopartners Inc, a late-stage … said Richard Muruve, CEO, Arch Biopartners.
The cardiac surgery-associated acute … survival.
LSALT peptide is Arch Biopartners’ lead drug candidate for … the scientific rationale for Arch Biopartners’ to use LSALT peptide …
-
Arch Biopartners doses first subject in trial of acute kidney injury treatment
12 Nov 2024 17:12 GMT
Canadian clinical trial company Arch Biopartners has dosed the first patient … in pre-clinical models.
Arch Biopartners CEO Richard Muruve said: “We … .”
In addition to Canada, Arch Biopartners has also begun recruiting and …
-
Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
11 Nov 2024 13:07 GMT
… 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “ … rates.
About Arch Biopartners
Arch Biopartners Inc. is a … For more information on Arch Biopartners’ science and drug platform … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
11 Nov 2024 12:30 GMT
… 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the … rates. About Arch Biopartners Arch Biopartners Inc. is a … For more information on Arch Biopartners’ science and drug platform … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners Arranges Non-Brokered Private Placement
15 Oct 2024 22:23 GMT
… 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the … disclosed. About Arch Biopartners Arch Biopartners Inc. is a … For more information on Arch Biopartners’ science and drug platform … information relating to Arch Biopartners Inc., including our most …
-
Panthera Biopartners Joins Parexel Site Alliance Vaccine Network
10 Oct 2024 14:28 GMT
… Parexel.
10.10.24
Panthera Biopartners has become the first UK …
-
Panthera Biopartners Resurrects Oncology Division
24 Sep 2024 14:37 GMT
… contracts.
09.24.24
Panthera Biopartners has experienced a resurgence in …
-
Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)
11 Sep 2024 10:30 GMT
… (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the … mortality. About Arch Biopartners Arch Biopartners Inc. is a … For more information on Arch Biopartners’ science and drug platform … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)
11 Sep 2024 10:36 GMT
… 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “ … mortality.
About Arch Biopartners
Arch Biopartners Inc. is a … more information on Arch Biopartners’ science and drug platform … information relating to Arch Biopartners Inc., including our most …
About
© 1995-2025